MediGene appoints Arnd Christ as Chief Financial Officeras Successor to Dr. Thomas Klaue
MediGene AG announced that Chief Financial Officer Dr. Thomas Klaue will leave the company for different opinions in strategic directions of the company by mutual consent with the Supervisory Board in May 2010. Dr. Klaue will resign from office after the Annual Shareholders' Meeting on May 11, 2010, and his employment contract will cease in June 2010. Arnd Christ has been chosen to succeed Dr. Klaue as Chief Financial Officer. Mr. Christ has many years' management experience in the biotech and pharmaceuticals industry, and has held his current position as Chief Financial Officer at the Swiss biotechnology company NovImmune since 2007.
Arnd Christ has 15 years of international experience in business finance and management as well as mergers and acquisitions. In his capacity as Chief Financial Officer at the biotech company NovImmune SA, Geneva, Switzerland, he was responsible for the successful closing of one of the largest private financing rounds (CHF 62.5 million) in the European biotech industry. Prior to joining NovImmune, Mr. Christ held the position as Chief Financial Officer of Probiodrug AG, Halle, for 5 years, where he was responsible for several fund raising rounds as well as for the successful closing of a major asset sale to OSI Pharmaceuticals Inc. Before joining Probiodrug AG, Arnd Christ was finance manager at several subsidiaries of the Hoechst Group in Germany and UK. Arnd Christ studied at the Julius-Maximilians-Universität in Würzburg and holds a degree in business administration.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
